Clinical trial
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis…
NCT00464321 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00464321 |
|---|---|
| Title | Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS |
| Official title | A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Focal Segmental Glomerulosclerosis |
| Intervention type | Biological |
| Interventions | GC1008 |
| Enrollment | 16 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Apr 23, 2007 |
| Last update posted | Mar 19, 2014 |
| Countries | Germany, Italy, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: